These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23695808)

  • 1. I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
    Printz C
    Cancer; 2013 Jun; 119(11):1925-7. PubMed ID: 23695808
    [No Abstract]   [Full Text] [Related]  

  • 2. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Clinical Trial Designs Hasten Approvals for Targeted Therapies.
    Schmidt C
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 6. Expediting the availability of drugs for US patients with cancer.
    Farrell AT; Pazdur R; von Eschenbach AC
    Nat Clin Pract Urol; 2008 Dec; 5(12):654-6. PubMed ID: 19050708
    [No Abstract]   [Full Text] [Related]  

  • 7. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 8. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iressa failure raises fears about accelerated approvals.
    Frantz S
    Nat Rev Drug Discov; 2005 Feb; 4(2):94-5. PubMed ID: 15756753
    [No Abstract]   [Full Text] [Related]  

  • 12. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical endpoints in trials of drugs for cancer: time for a rethink?
    Koopmans PP
    BMJ; 2002 Jun; 324(7350):1389-91. PubMed ID: 12052814
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More trials, fewer tribulations.
    Eisenstein M
    Sci Am; 2014 Jul; 311(1):S9-11. PubMed ID: 24974700
    [No Abstract]   [Full Text] [Related]  

  • 16. Priority-setting decisions for new cancer drugs.
    Millar A
    Lancet; 2002 Apr; 359(9316):1524; author reply 1524-5. PubMed ID: 11988280
    [No Abstract]   [Full Text] [Related]  

  • 17. Priority-setting decisions for new cancer drugs.
    Wheatley K; Djulbegovic B; Glasmacher A
    Lancet; 2002 Apr; 359(9316):1525. PubMed ID: 11988282
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of health-related quality-of-life measures in oncology drug product applications: issues and concerns.
    Sridhara R; Chen G; Chi GY; Griebel DJ
    J Biopharm Stat; 2004 Feb; 14(1):23-30. PubMed ID: 15027498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase 1 clinical trials nursing: determining safety and side effects on the road approval.
    Lindberg D
    ONS Connect; 2012 Jul; 27(7):10-4. PubMed ID: 22855983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.